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Abstract. Background/Aim: Apoptosis-inducing factor,
mitochondrion-associated 2 (Aifm2), is a DNA-binding
oxoreductase protein that promotes apoptosis. To assess its
potential role in erythropoiesis we analyzed the effects of
Aifm2 loss-of-function in the murine erythroleukemia line
(MEL). Materials and Methods: MEL cells were transfected
with siRNA targeting Aifm2 for 24 h and evaluated by cell
counting, flow cytometry with annexin V and PI staining and
gene expression analysis. Results: Aifm2 knockdown did not
affect the apoptotic status of MEL cells. However, Aifm2
knockdown significantly increased expression of the
erythropoietic transcription factor Klf1 (2.9±0.2-fold, p<0.05)
and decreased α- and β-globin expression (0.6±0.2-fold,
p<0.05 and 0.5±0.2-fold, p<0.01). Conclusion: Aifm2 may
function in differentiation of erythroid MEL cells in vitro.
Erythropoiesis is a process in which hematopoietic stem cells
give rise to functional and mature erythrocytes, which are
produced daily and circulate throughout the body to deliver
oxygen (1). Abnormalities in erythropoiesis result in anemia,
which impairs quality of life due to inadequate oxygen-
associated symptoms, such as tiredness, headaches, lack of
concentration and dizziness (2-4). Erythropoietic homeostasis
is tightly regulated by intrinsic factors, such as the
transcription factors Gata-binding protein 1 (Gata1) and
Krüppel-like factor 1 (Klf1, also known as Eklf or Nan). The
erythropoietic system also requires proper control of apoptosis
to maintain a balance between erythroid cell production and
destruction (5). Murine erythroleukemia (MEL) cells, an acute
leukemic blast line with the capacity to differentiate into
erythroid cells, has been a useful model for the delineation of
molecular mechanisms underlying erythroid differentiation (6-
9). For instance, doking protein 2, which provides a platform
for assembly of signaling molecules, is a novel intrinsic factor
to regulate Klf1 transcription through Klf1 promoter binding
in the MEL cells (9).
Apoptosis-inducing factors or mitochondria-associated
proteins are a family of flavoproteins implicated in caspase-
independent apoptosis (10). The absence of poly (ADP-
ribose) glycohydrolase reportedly promotes increased cell
death mediated by these factors (11), which translocate from
mitochondria to the cytoplasm and then to the nucleus in
order to promote cell death. Consequently, apoptosis-inducing
factors induce chromatin condensation and DNA
fragmentation (12). Apoptosis-inducing factor mitochondrion-
associated 2 (Aifm2), a member of this family, is present in
the mitochondrial inter-membrane space (13) and functions
in p53/TP53-dependent apoptosis (14). Our preliminary data
showed that MEL cells express Aifm2 mRNA and Aifm2
protein but its function in those cells remains unknown. To
assess the potential function of Aifm2 in regulating
erythropoiesis, we knocked-down Aifm2 mRNA in the MEL
cell line and evaluated expression of erythropoiesis-related
genes. Our findings suggest that Aifm2 regulates expression
of the erythroid transcription factor encoded by Klf1, thus
suggesting a potential role in mouse erythroid differentiation. 
Materials and Methods
Cell lines. MEL cells (kindly provided by Dr. Brand, Ottawa Health
Research Institute, Ottawa, Canada) were cultured in RPMI-1640
with L-glutamine and phenol red (Wako Pure Chemical Industries,
Ltd., Osaka, Japan) containing 10% fetal bovine serum (FBS) and
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10 units/ml penicillin and 10 mg/ml streptomycin (Sigma-Aldrich,
Saint Louis, MO, USA). Cells were passaged every 3-4 days.
siRNA transfection. One hundred thousand cells were cultured for 
12 h in 24-well plates in RPMI-1640 containing 1% FBS without
antibiotics before siRNA transfection. siRNA-Lipofectamine™ 2000
(Life Technologies, Palo Alto, CA, USA) complexes were prepared
according to the manufacturer’s protocol. For Aifm2 knockdown, we
used pre-designed Aifm2 siRNA (Sigma-Aldrich). Silencer® Negative
Control No.1 siRNA (Ambion, Austin, TX, USA) served as control
siRNA. Sixty pmole Aifm2 siRNA was diluted in 50 μl of Opti-MEM®
I Reduced Serum Medium (Life Technologies). In a separate tube, 2 μl
of Lipofectamine™ 2000 was diluted in 50 μl of Opti-MEM® I
Reduced Serum Medium (Life Technologies) and incubated at room
temperature for 5 min. Then, siRNA and Lipofectamine™ 2000 were
mixed and incubated at room temperature for 20 min to allow
formation of complexes, which were then added to cells and incubated
at 37˚C with 5% of CO2 for 24 h. To induce erythroid differentiation,
dimethyl sulfoxide (DMSO) was added at 2% final concentration at
24 h post-siRNA transfection and cells were collected 24 h later for
gene expression analysis. 
May-Grünwald-Giemsa staining. Twnety-four hours after siRNA
transfection, MEL cells were spread onto glass slides (Matsunami Glass
ind., Ltd., Osaka, Japan) using a CytoSpin™4 cytocentrifuge (Thermo
Fisher Scientific, Waltham, MA, USA) at 450 rpm for 7 min, rapidly air
dried and then fixed and stained using May-Grünwald reagent (Muto
Pure Chemicals, Tokyo, Japan) at room temperature for 5 min. After a
brief wash in tap water, cells were incubated with PBS (pH=6.4) for 
2 min and then stained with diluted Giemsa solution (1:18; Muto Pure
Chemicals, Tokyo, Japan) at room temperature for 30 min. After an
additional tap water wash, slides were air-dried and covered with glass
coverslips with a drop of MGK-S mounting solution (Matsunami
glass). Cells were imaged using an Olympus CKX41 microscope
(Olympus, Tokyo, Japan).
Immunocytochemistry. Harvested cells were centrifuged onto glass
slides (Matsunami Glass) using a CytoSpin4 (Thermo Fisher
Scientific) at 450 rpm for 7 min and air-dried overnight. Cells were
then fixed in 1% paraformaldehyde at 4˚C for 30 min. After washing
three times with PBS, cells were incubated with PBS containing
0.05% Triton X-100 at room temperature for 15 min, washed again
three times with PBS and then blocked with PBS containing 1%
bovine serum albumin (BSA) at room temperature for 30 min to
prevent non-specific antibody binding. Cells were incubated with
rabbit anti-mouse Aifm2 (1:200; Thermo Fisher Scientific, Waltham,
MA, USA) primary antibody at 4˚C overnight in the dark. After three
PBS rinses, cells were covered with diluted goat anti-rabbit IgG
antibody conjugated with AlexaFluor488 (1:400; Invitrogen, Carlsbad,
CA, USA) and TOTO-3 iodide (1:1,500; Invitrogen) at room
temperature for 30 min in the dark. After three PBS washes, cells were
coverslipped with one drop of anti-fade mounting medium (Dako
Corporation, Glostrup, Denmark). Images were acquired using a
FluoView 1000 confocal microscope (Olympus).
RNA extraction and quantitative real-time polymerase chain reaction
(qRT-PCR). Total RNA was extracted from harvested cells using an
RNAqueous-4PCR™ Kit (Life Technologies) and mRNA was reverse
transcribed into cDNA using a High-Capacity RNA-to-cDNA™ Kit
(Life Technologies). Aifm2, Gata1, Klf1, α-Globin (Hba1), β-Globin
(Hbb) and β-actin (Actb) expression was evaluated using
StepOnePlus™ real-time PCR (Life Technologies) reagent with
TaqMan® Gene Expression Assays (Life Technologies). Actb served
as an internal control. Relative expression of each gene was calculated
using a standard curve method. Relative expression of Bax, Bcl2,
Mcl1, Myc and Ccnd1 was assessed using Fast SYBR® Green Master
Mix (Life Technologies) with the following primers: Bax, forward: 
5’- AGTGTCTCCGGCGAATTGG-3’, reverse: 5’-AGCTGCCACC
CGGAAGA-3’; Bcl2, forward: 5’-GAGGCTGGGATGCCTTTGT-3’,
reverse: 5’-CCAGGTATGCACCCAGAGTGA-3’; Mcl1, forward: 
5’-GGGCTGGTCTGGCATATCTA-3’, reverse: 5’-GCAGCTTCAA
GTCCACCTTC-3’; Myc, forward: 5’-CCTAGTGCTGCATGAGG
AGA-3’, reverse: 5’-TCTTCCTCATCTTTTGCTCTTC-3’; Ccnd1,
forward: 5’-CGCCCTCCGTATCTTACTTCAA-3’, reverse: 5’-CTCA
CAGACCTCCAGCATCCA-3’; and Actb, forward: 5’-GCTCTGGCT
CCTAGCACCAT-3’, reverse: 5’-GCC ACCGATCCACACAGAGT-3’. 
Flow cytometry and apoptosis analysis. For apoptosis analysis, cells
were resuspended after two brief PBS washes in annexin V binding
buffer (BioLegend, San Diego, CA, USA) at 1.0×106 cells/ml. After
transferring 100 μl of the cell suspension to a test tube, cells were
stained with allophycocyanin (APC)-conjugated annexin V and
propidium iodide (PI) (Invitrogen) and then incubated at room
temperature for 15 min in the dark. After addition of 400 μl annexin
V binding buffer, stained cells were analyzing by BD FACS Area
(BD Bioscience, San Jose, CA, USA). Cells were fractionated based
on the following criteria: annexin V−/PI− were defined as non-
apoptotic (living cells), annexin V+/PI− as early apoptotic and
annexin V+/PI+ as late apoptotic cells.
Statistical analysis. Results are presented as means±standard
deviation (SD). For statistical tests, we used Student’s t-test to
compare two samples: Aifm2 siRNA-transfected and control siRNA-
transfected cells. All p-values less than 0.05 were considered
statistically significant.
Results
Aifm2 protein and mRNA expression in MEL cells. MEL cell
did express Aifm2 mRNA. When we compared the level of
Aifm2 mRNA with Dok2 mRNA (9) by qRT-PCR, relative
expression of Aifm2 mRNA was 3.2±0.3-fold higher than
that of Dok2 mRNA in MEL cells (p<0.05; Figure 1A).
These data show the possible role of Aifm2 in MEL cells. To
investigate Aifm2 protein expression and localization, we
performed immunocytochemical analysis of cultured MEL
cells with an Aifm2 antibody. Confocal microscopy images
revealed that Aifm2 protein was present in the cytoplasm and
nucleus of MEL cells (Figure 1B).
Aifm2 loss-of-function in MEL cells. To assess Aifm2 function,
we knocked-down Aifm2 mRNA in MEL cells using siRNA.
Twenty-four hours after siRNA transfection, we assayed
knockdown efficiency by qRT-PCR and found that Aifm2
transcripts had decreased by 76.3±0.0% relative to control
siRNA-transfected cells (Figure 2A). When we assessed cell
morphology at 24 h post-transfection by light microscopy, we
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found that most cells exhibited a round shape, same as before
siRNA transfection. Relative to controls, some Aifm2 siRNA-
transfected cells appeared swollen (Figure 2B, arrows). May-
Grünwald-Giemsa staining revealed that there was no obvious
morphological differences between Aifm2 siRNA-transfected
and control samples after 24 h of siRNA transfection. Blue-
colored cytoplasm, vacuoles and multi-nuclear cells were
observed in both samples (Figure 2C).
Analysis of apoptotic status of Aifm2 siRNA-transfected MEL
cells. After 24 h of siRNA transfection, we counted viable and
dead cells in both control and Aifm2 siRNA-transfected
samples. While we observed no differences in the number of
viable cells in control and Aifm2 siRNA-transfected cells
(199,200±31,146.8 cells and 205,166±11,918.2 cells,
respectively; Figure 3A, upper pannel), we observed a
significant difference in the number of dead cells in control
and Aifm2 siRNA-transfected cells  (30,566±2,974.0 and
17,300±2,605.0, respectively, p<0.05; Figure 3A, lower
pannel). To further assess the apoptotic status of the cells, we
performed annexin V and PI staining (Figure 3B). Living cells
(annexin V−/PI−), early apoptotic (annexin V+/PI−) and late
apoptotic (annexin V+/PI+) cells were evaluated by flow
cytometry. As shown in Figure 2C, most MEL cells were early
apoptotic (annexin V+/PI−) cells, namely, 78.1±3.7% in Aifm2
siRNA-transfected and 81.4±0.0% in control cells. Among the
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Figure 1. Expression of Aifm2 in MEL cells. (A) Relative expression of Aifm2 and Dok2 mRNAs in MEL cells, as measured by quantitative real-
time polymerase chain reaction (qRT-PCR). Aifm2 transcripts are expressed at levels 3.2±0.3-fold (p<0.05) higher than those of Dok2. (B)
Immunocytochemical images of Aifm2 protein (green) in MEL cells. Scale bar=20 μm. Nuclear DNA is stained with TOTO-3 iodide (blue). Aifm2
protein is localized to both the cytoplasm and nucleus.
Figure 2. Morphological analysis of MEL cells after Aifm2 knockdown. (A) Relative expression of Aifm2 mRNA 24 h after siRNA transfection. Aifm2
mRNA levels were decreased 76% relative to MEL cells transfected with control siRNA (p<0.05). (B) Microscopic images of MEL cells 24 h after
transfection with control (left) or Aifm2 (right) siRNA. Arrows indicate swollen cells. Scale bar=20 μm. (C) May-Grünwald-Giemsa staining of
MEL cells 24 h after transfection with control (left) or Aifm2 (right) siRNA. Scale bar=50 μm.
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Figure 3. Analysis of apoptosis in MEL cells after Aifm2 knockdown. (A) The number of viable and dead MEL cells 24 h after siRNA transfection.
No significant difference was observed in the number of viable cells between groups (upper panel), while we observed a reduced number of dead
cells (lower panel, p<0.05) in Aifm2 siRNA-transfected versus control siRNA-transfected cells. (B) Flow cytometry analysis of apoptosis using
annexin V and propidium iodide (PI). Shown are representative flow cytometry plot and gate settings. Percentages were calculated with gates for the
following cell populations: annexin V−/PI−, living cells; annexin V+/PI−, early apoptotic cells; and annexin V+/PI+, late apoptotic cells. (C)
Percentage of cells shown in B. Most cells were early apoptotic cells in both Aifm2 siRNA-transfected (78.1±3.7%) and control siRNA-transfected
(81.4±0.0%) cells. No significant difference was observed in any population between Aifm2 siRNA-transfected and control cells. (D) Relative
expression of the pro-apoptotic genes Bax and Bcl2, the cell survival-related gene Mcl1 and the cell proliferation-related genes Myc and Ccnd1. By
24 h post siRNA transfection, Bax expression increased 2.3±0.6-fold (p<0.05) in Aifm2 siRNA-transfected versus control cells.
three populations evaluated, the percentage of living (annexin
V−/ PI−) cells was the lowest: 7.6±0.8% in Aifm2 siRNA-
transfected cells and 7.3±0.9% in controls. We observed no
significant change in percentages of early apoptotic cells in
the Aifm2 siRNA-transfected and control cells 24 h post-
transfection (p=0.20; Figure 3C). Finally, we did not observe
any significant difference in the percentage of late apoptotic
cells between Aifm2 siRNA-transfected and control cells
(13.8±3.3% and 10.8±0.8%, respectively, p=0.20; Figure 3C). 
To further investigate Aifm2 function in apoptosis, cell
survival and cell proliferation, we examined expression of the
apoptosis-related genes Bax and Bcl2, (15-18), the cell
survival-related gene Mcl1 (19, 20) and the proliferation-related
genes Myc and Ccnd1 (21-24) by qRT-PCR (Figure 3D). Bax
mRNA increased by 2.3±0.6-fold in Aifm2 siRNA-transfected
cells (p<0.05) compared to controls. However, there was no
significant difference in expression of Bcl2 (p=0.95) and Mcl1
transcripts (p=0.41) nor was there a significant difference in
Myc and Cdnd1 transcript levels 24 h post-siRNA transfection
(p=0.09 and p=0.71, respectively). 
Aifm2 knockdown increases Klf1 expression. To further
investigate Aifm2 function in erythropoiesis, we assessed
expression of the erythroid differentiation-related genes
Gata1, Klf1, as well as α- and β-Globin by qRT-PCR 24 h
after siRNA transfection (Figure 4A). Among these genes,
Klf1 showed a significant increase (2.9±0.2-fold relative to
controls) (p<0.001) in Aifm2 siRNA-transfected cells.
Relative α-Globin (Hba1) and β-Globin (Hbb) expression
significantly decreased by 0.6±0.2-fold (p<0.05) and
0.5±0.2-fold (p<0.01), respectively. 
We next examined expression of these genes after
harvesting MEL cells that had been treated with DMSO to
induce erythroid differentiation (Figure 4B). After 24 h of
DMSO treatment, Hbb mRNA expression significantly
increased by 1.6±0.2-fold (p<0.05) in Aifm2 siRNA-
transfected cells relative to controls, although we observed no
significant differences in Gata1, Klf1 and Hba1 mRNA levels.
Discussion
Herein we report that Aifm2 loss-of-function alters the
expression of erythroid differentiation-related genes in MEL
cells in vitro. Aifm2 is well-known as an apoptosis-inducing
protein localized primarily to the mitochondrial outer membrane
(25). Aifm2 protein contains oxidoreductase domain, which
functions in induction of large-scale DNA breaks in apoptosis
and Aifm2 protein levels increase with apoptotic activity (26). In
our study, we observed high Aifm2 mRNA expression in MEL
cells (Figure 1A) and that Aifm2 protein resides in both the
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Figure 4. Expression of erythroid differentiation-related genes following Aifm2 knockdown. (A) Relative mRNA expression of the erythroid
differentiation-related genes Gata1, Klf1, α-Globin and β-Globin 24 h after siRNA transfection. Relative Klf1 expression increased 2.9±0.2-fold
(p<0.05) and that of α- and β-Globin mRNA decreased 0.6±0.1-fold (p<0.05) and 0.5±0.2-fold (p<0.05), respectively, in Aifm2 siRNA-transfected
cells compared to controls. (B) Relative expression of differentiation-related genes after dimethyl sulfoxide (DMSO) treatment of Aifm2 siRNA-
transfected cells. Twenty-four hours post siRNA transfection, DMSO was added to cultures and gene expression was analyzed 24 h later. β-Globin
mRNA expression significantly increased by 1.4±0.2-fold in Aifm2 siRNA-transfected versus control cells. (p<0.05). 
cytoplasm and nucleus (Figure 1B). Mouse Aifm2 reportedly
translocates from mitochondria to the nucleus to initiate
apoptosis (12) suggesting a similar mechanism in MEL cells.
To further a potential Aifm2 function in MEL cell apoptosis, we
performed loss-of-function analysis by transfecting MEL cells
with siRNA targeting Aifm2. Despite its characterization as an
apoptosis-inducing protein (25), we did not observe significant
changes in cell morphology, in the number of viable cells, or in
apoptotic status, as determined by annexin V and PI staining,
between Aifm2 siRNA-transfected and control siRNA cells
(Figures 2 and 3). We also observed no change in expression of
genes that antagonize apoptosis (Bcl2) or enhance cell survival
(Mcl1) or proliferation (Myc and Ccnd1). By contrast, we
observed an increased expression of pro-apoptotic Bax mRNA.
It is reported that Bax induces apoptosis of human K562
erythroleukemia cells in a caspase-dependent manner (27).
Relevant to apoptosis, the discrepancy between ours and
previous reports may be explained by compensatory activity of
other members of the apoptosis-inducing factor family, such as
Aifm1 or Aifm3. Although, apoptosis is a fundamental process
in all metazoans (28), it requires diverse signaling pathways
(29). Therefore, additional approaches will be required to assess
potential roles played by other apoptosis-inducing factors at
additional time points in MEL cells. 
Given that we observed no apparent difference in apoptosis in
Aifm2 knockdown versus control MEL cells, we focused on
Aifm2’s effect on erythroid differentiation since MEL cells
constitute a suitable model to study that process (9, 30). Intrinsic
factors, such as the transcription factors Gata1 and Klf1 (7),
regulate erythropoiesis to maintain cellular homeostasis. Gata1
reportedly regulates Klf1 transcription, which is further linked
to the activation of Globin transcription (7). In our study, Aifm2
knockdown by 76.3% resulted in a 2.9±0.2-fold increase in Klf1
mRNA expression compared to controls (Figure 4A) suggesting
that Aifm2 antagonizes Klf1 transcription. Klf1 functions in
regulation of erythroid commitment, globin switching and
maturation of erythrocytes (31). Unlike Klf1, expression of
Globin mRNAs decreased in Aifm2 knockdown cells, although
Klf1 reportedly activates Globin transcription (32). To further
evaluate the effect of Aifm2 on Globin expression, we induced
erythroid differentiation of MEL cells by DMSO treatment (8)
and observed a significant increase in β-Globin mRNA
(1.4±0.2-fold, p<0.05) in Aifm2 knockdown relative to control
cells (Figure 4B). 
In conclusion, we show that Aifm2 potentially regulates
mouse erythroid differentiation in a MEL cell model. Further
investigations are required to define mechanisms underlying
Aifm2’s activity in regulating erythropoiesis.
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